)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Diagonal Bio
Diagonal Bio (DIABIO) investor relations material
Diagonal Bio has been delisted
Diagonal Bio Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary31 Oct, 2025
Executive summary
Achieved key commercial milestone with Stall Courant's order of LAMPlify and a 36-month leasing agreement, expanding presence in the equine diagnostics market.
Launched a new test for Equine Herpesvirus type 2 (EHV-2), broadening the product portfolio for equine health.
Filed a Swedish patent application for a computational method improving LAMP primer design, and received a Japanese patent grant for a proprietary detection method.
Initiated collaboration with the Swedish Veterinary Agency to evaluate equine coronavirus testing, supporting scientific validation and market expansion.
Launched a new website to strengthen commercial presence and focus on the animal health market.
Financial highlights
Net sales for Q3 2025 were 45 KSEK, up from 0 KSEK in Q3 2024.
Net loss after financial items was -2,042 KSEK, compared to -1,242 KSEK in the same quarter last year.
Cash flow for the quarter was -1,002 KSEK, an improvement from -2,428 KSEK in Q3 2024.
Cash and cash equivalents at period end were 1,737 KSEK, nearly unchanged from 1,730 KSEK a year earlier.
Investments in intangible assets (patents and trademarks) totaled 108 KSEK, and capitalized development expenses were 238 KSEK.
Outlook and guidance
Focus remains on expanding LAMPlify's market presence and leveraging the growing IP portfolio for long-term value.
Ongoing collaborations and new product launches are expected to drive further commercial and scientific progress.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Diagonal Bio
- Milestones in product, patent, and financing position the company for diagnostics market growth.DIABIO
Q2 2025 - First LAMPlifyⓇ sale and expanded veterinary pilots mark key milestones amid ongoing losses.DIABIOQ3 2024
- Strategic advances in veterinary diagnostics and SEK 18M raised despite no Q2 sales.DIABIOQ2 2024
- Diagonal Bio posts revenue growth, secures funding, and advances diagnostics platform.DIABIOQ1 2025
- LAMPlifyⓇ achieved first sales and expanded pilots as Diagonal Bio improved financials.DIABIOQ4 2024
Diagonal Bio
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Diagonal Bio AB operates as a biotechnology company in Sweden. The company is focused on the development of drug candidate for treatment of diabetes and obesity, based on its technology for targeting the GLP-1 receptor. The company also develops small molecules for pharmaceutical and diagnostic purposes. It offers DiabNext, which is in Phase II trial for dibenzo-p-dioxin (DCDX)-induced significant reduction in pulmonary hypertension syndrome (PH). The company is based in Lund, Sweden.